Table 5.

 Pharmacological treatment of men with heart failure (HF) in Scotland, April 1999–March 2000

Treatment	Age group (years)
	45–64	65–74	75–84	⩾85	<75	⩾75	All ages
Number	64	132	164	74	201	238	439
Furosemide	36	80	114	49	119	163	282
	(56.3%)	(60.3%)	(69.5%)	(66.2%)	(59.2%)	(68.5%)	(64.2%)
Any diuretic	47	105	139	58	155	197	352
	(73.4%)	(79.6%)	(84.8%)	(78.4%)	(77.1%)	(82.8%)	(80.2%)
ACE inhibitor	39	71	69	21	111	90	201
	(60.9%)	(53.8%)	(42.1%)	(28.4%)	(55.2%)	(37.8%)	(45.8%)
ARB	4	5	8	1	9	9	18
	(6.3%)	(3.8%)	(4.9%)	(1.4%)	(4.5%)	(3.8%)	(4.1%)
β Blocker	20	34	33	14	55	47	102
	(31.3%)	(25.8%)	(20.1%)	(18.9%)	(27.4%)	(19.8%)	(23.2%)
Spironolactone	12	16	16	4	28	20	48
	(18.8%)	(12.1%)	(9.8%)	(5.4%)	(13.9%)	(8.4%)	(10.9%)
Digoxin	17	30	43	15	47	58	105
	(26.6%)	(22.7%)	(26.2%)	(20.3%)	(23.4%)	(24.4%)	(23.9%)
Any HF treatment	57	114	149	61	175	210	385
	(89.1%)	(86.4%)	(90.9%)	(82.4%)	(87.1%)	(88.2%)	(87.7%)

ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker.